Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy may offer lasting pain control for facial nerve condition

NCT ID NCT07304453

Symptom relief Sponsor: Karbala University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a combination of nucleotides and B vitamins (Nucleo CMP and Neurorubine) could provide better and longer-lasting pain relief than the standard drug carbamazepine for people with trigeminal neuralgia, a severe facial pain condition. 38 adults with classic trigeminal neuralgia were randomly assigned to one of the two treatments. The goal was to see if the new combo could control pain during treatment and keep pain away after stopping it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nucleo CMP (cytidine monophosphate) and Neurorubine (vitamins B1, B6, B12)
What this could lead to
If it works, this could offer a new way to manage trigeminal neuralgia pain that lasts even after stopping treatment, potentially reducing side effects from standard drugs.
What could go wrong
This is a small Phase 2 trial with only 38 participants, so results may not apply to everyone. The combination therapy may not work better than carbamazepine, and its long-term safety is not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

38 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: .• Age between 18-80 years * Clinical diagnosis of classical trigeminal neuralgia according to International * Headache Society (IHS) diagnostic criteria * Pain duration of at least 3 months * Baseline Visual Analogue Scale (VAS) pain score greater than or equal to 4 * Ability to provide informed consent and comply with study procedures * No contraindications to study medications Exclusion Criteria: * Secondary trigeminal neuralgia due to underlying pathology * Atypical facial pain or other orofacial pain conditions * Significant cardiovascular, hepatic, or renal disease * Pregnancy or lactation * Current use of anticonvulsants or other neuropathic pain medications * History of allergic reactions to study medications * Cognitive impairment preventing reliable pain assessment * Concurrent participation in other clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuropathic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuralgia trigeminal neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuropathic pain Trigeminal neuralgia

Contacts and locations

Locations

  • Oral Medicine Clinic, College of Dentistry, University of Kerbala

    Karbala, Kerbala, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.